6AN-1644 #

DOCKET NO. 17282CIP(AP)
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

n Re Application of Steward et al

Serial No: 09/548,409

Confrm. No: 7255

Filed: April 13, 2000

For: METHODS AND COMPOSITIONS

FOR THE TREATMENT OF

PANCREATITIS

Group Art Unit: 1644

Examiner: Clemens, K

RECEIVED

JUN 1 5 2001

TECH CENTER 1600/2900

REPLY

Box Non Fee Amendment-Restriction Requirement Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

This Reply is responsive to the Restriction Requirement mailed April 18, 2001.

First, Applicants would like to thank the Examiner for renumbering the claims to be consistent with 37 CFR 1.127; Applicants regret the error necessitating the Examiner's action in this regard.

The Examiner has made a Restriction Requirement pursuant to 35 USC § 121, in which claims 1-13 have been identified as Group I (composition claims) and claims 14-19 as Group II (method claims).

Applicants elect to prosecute Examiner's Group I, ; currently comprising claims 1-13.

The Examiner has also required an election of species within Group I.

Specifically, the Examiner has requested that a species of A) the translocational element and B) the therapeutic element be elected. Applicants elect to prosecute the species within Group I which are compositions comprising: the translocation domain of the

Docket No. 17282CIP(...) Serial No. 09/548,409

heavy chain of a *Clostridium botulinum* neurotoxin and a therapeutic element comprising the BoNT/A or E endopeptidase.

Claims 1-14 each read on the elected species.

No fee or certification is thought to be required in connection with this communication. If Applicant is in error in this regard, please use Deposit Account 01-0885 for payment of any fee that may be due.

Respectfully submitted,

Date: 5[5] Carlos A. Fisher
Registration No. 36,510

ALLERGAN, INC. Legal Department-T2-7H 2525 Dupont Drive Irvine, CA 92612

Telephone: (714) 246-4920 Facsimile: (714) 246-4249